Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
HealthPartners Institute
With
Eli Lilly and Company
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female (if of child-bearing age must practice appropriate birth control such as tubal ligation, oral contraceptives, abstinence or vasectomized partner during the duration of the study)
Previously diagnosed with type 2 diabetes
Age 21 and older
Treated with metformin, a sulfonylurea, a thiazolidinedione, a combination or metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione (approved FDA indications)
HbA1c 7.1-11%, unless subject has been using exenatide prior to study; in that case, there is no restriction on HbA1c level.
Willing to give informed consent
Motivated and capable of following the protocol and instructions provided by the healthcare professional
Available for the study on the scheduled visit days
Any concomitant medical condition that would likely affect the evaluation of CGM device performance as determined by the investigator such as dermatological conditions or myxedema.
Clareo Health | Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide
